Skip to main content
Top
Published in: Current Hematologic Malignancy Reports 4/2017

01-08-2017 | Health Economics (N Khera, Section Editor)

Equal Treatment and Outcomes for Everyone with Multiple Myeloma: Are We There Yet?

Authors: Sikander Ailawadhi, Kirtipal Bhatia, Sonikpreet Aulakh, Zahara Meghji, Asher Chanan-Khan

Published in: Current Hematologic Malignancy Reports | Issue 4/2017

Login to get access

Abstract

Multiple myeloma treatment has changed tremendously over recent years leading to overall improvement in patient outcomes. With therapeutic advancements, patient care has become increasingly complex and variability is seen in healthcare delivery as well as outcomes when various patient subgroups are analyzed based on sociodemographic factors. It is imperative to understand this variability so that while overall the outcomes get better, specific focus is placed on subgroups that may remain disadvantaged and may not be able to fully access the advancements in therapeutics. Research in multiple myeloma has specifically looked at several such patient subgroups based on socioeconomic status, age, race/ethnicity, insurance carrier, and geographic location that may affect healthcare utilization and patient outcomes. Exploring and understanding these would certainly help address disparities and lead to further equity in healthcare access and, hopefully, patient outcomes.
Literature
2.
go back to reference Dingli D, Ailawadhi S, Bergsagel PL, Buadi FK, Dispenzieri A, Fonseca R, et al. Therapy for relapsed multiple myeloma: guidelines from the Mayo stratification for myeloma and risk-adapted therapy. Mayo Clin Proc. 2017; doi:10.1016/j.mayocp.2017.01.003. Dingli D, Ailawadhi S, Bergsagel PL, Buadi FK, Dispenzieri A, Fonseca R, et al. Therapy for relapsed multiple myeloma: guidelines from the Mayo stratification for myeloma and risk-adapted therapy. Mayo Clin Proc. 2017; doi:10.​1016/​j.​mayocp.​2017.​01.​003.
4.
go back to reference Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122–8. doi:10.1038/leu.2013.313.CrossRefPubMed Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122–8. doi:10.​1038/​leu.​2013.​313.CrossRefPubMed
6.
11.
go back to reference Kelly KR, Yang D, Sharma M, Roy V, Chanan-Khan A, Ailawadhi S. Persistent racial/ethnic disparities in outcomes for multiple myeloma: a SEER-Database update. Blood. 2016;128:1191. (Abstract) Kelly KR, Yang D, Sharma M, Roy V, Chanan-Khan A, Ailawadhi S. Persistent racial/ethnic disparities in outcomes for multiple myeloma: a SEER-Database update. Blood. 2016;128:1191. (Abstract)
14.
go back to reference Landgren O, Graubard BI, Katzmann JA, Kyle RA, Ahmadizadeh I, Clark R, et al. Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey. Leukemia. 2014;28(7):1537–42. doi:10.1038/leu.2014.34.CrossRefPubMedPubMedCentral Landgren O, Graubard BI, Katzmann JA, Kyle RA, Ahmadizadeh I, Clark R, et al. Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey. Leukemia. 2014;28(7):1537–42. doi:10.​1038/​leu.​2014.​34.CrossRefPubMedPubMedCentral
16.
go back to reference Kaya H, Peressini B, Jawed I, Martincic D, Elaimy AL, Lamoreaux WT, et al. Impact of age, race and decade of treatment on overall survival in a critical population analysis of 40,000 multiple myeloma patients. Int J Hematol. 2012;95(1):64–70. doi:10.1007/s12185-011-0971-z.CrossRefPubMed Kaya H, Peressini B, Jawed I, Martincic D, Elaimy AL, Lamoreaux WT, et al. Impact of age, race and decade of treatment on overall survival in a critical population analysis of 40,000 multiple myeloma patients. Int J Hematol. 2012;95(1):64–70. doi:10.​1007/​s12185-011-0971-z.CrossRefPubMed
17.
go back to reference Costa LJ, Brill IK, Omel J, Godby K, Kumar SK, Brown EE. Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. Blood Advances. 2017;1(4):282–7.CrossRef Costa LJ, Brill IK, Omel J, Godby K, Kumar SK, Brown EE. Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. Blood Advances. 2017;1(4):282–7.CrossRef
18.
go back to reference Morgan GJ, Davies FE, Linet M. Myeloma aetiology and epidemiology. Biomed Pharmacother. 2002;56(5):223–34.CrossRefPubMed Morgan GJ, Davies FE, Linet M. Myeloma aetiology and epidemiology. Biomed Pharmacother. 2002;56(5):223–34.CrossRefPubMed
21.
go back to reference Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst. 2002;94(5):334–57.CrossRefPubMed Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst. 2002;94(5):334–57.CrossRefPubMed
22.
go back to reference Bhatnagar V, Wu Y, Goloubeva OG, Ruehle KT, Milliron TE, Harris CG, et al. Disparities in black and white patients with multiple myeloma referred for autologous hematopoietic transplantation: a single center study. Cancer. 2015;121(7):1064–70. doi:10.1002/cncr.29160.CrossRefPubMed Bhatnagar V, Wu Y, Goloubeva OG, Ruehle KT, Milliron TE, Harris CG, et al. Disparities in black and white patients with multiple myeloma referred for autologous hematopoietic transplantation: a single center study. Cancer. 2015;121(7):1064–70. doi:10.​1002/​cncr.​29160.CrossRefPubMed
26.
go back to reference Fiala MA, Finney JD, Stockerl-Goldstein KE, Tomasson MH, DiPersio JF, Vij R, et al. Re: disparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myeloma. Biol Blood Marrow Transplant. 2015;21(7):1153–4. doi:10.1016/j.bbmt.2015.03.005.CrossRefPubMed Fiala MA, Finney JD, Stockerl-Goldstein KE, Tomasson MH, DiPersio JF, Vij R, et al. Re: disparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myeloma. Biol Blood Marrow Transplant. 2015;21(7):1153–4. doi:10.​1016/​j.​bbmt.​2015.​03.​005.CrossRefPubMed
27.
go back to reference Al-Hamadani M, Hashmi SK, Go RS. Use of autologous hematopoietic cell transplantation as initial therapy in multiple myeloma and the impact of socio-geo-demographic factors in the era of novel agents. Am J Hematol. 2014;89(8):825–30. doi:10.1002/ajh.23753.CrossRefPubMed Al-Hamadani M, Hashmi SK, Go RS. Use of autologous hematopoietic cell transplantation as initial therapy in multiple myeloma and the impact of socio-geo-demographic factors in the era of novel agents. Am J Hematol. 2014;89(8):825–30. doi:10.​1002/​ajh.​23753.CrossRefPubMed
28.
go back to reference Costa LJ, Huang J-X, Hari PN. Disparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myeloma. Biology of Blood and Marrow Transplantation. 2015;21(4):701–6.CrossRefPubMed Costa LJ, Huang J-X, Hari PN. Disparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myeloma. Biology of Blood and Marrow Transplantation. 2015;21(4):701–6.CrossRefPubMed
30.
go back to reference Fiala MA, Wildes TM. Racial disparities in treatment use for multiple myeloma. Cancer. 2017. Fiala MA, Wildes TM. Racial disparities in treatment use for multiple myeloma. Cancer. 2017.
31.
go back to reference Ailawadhi S, Frank RD, Menghani R, Sharma M, Temkit M, Paulus SM, et al. Racial disparity in drug utilization among multiple myeloma patients: a SEER Medicare analysis. Blood. 2016;128:3542. (Abstract) Ailawadhi S, Frank RD, Menghani R, Sharma M, Temkit M, Paulus SM, et al. Racial disparity in drug utilization among multiple myeloma patients: a SEER Medicare analysis. Blood. 2016;128:3542. (Abstract)
33.
go back to reference Ailawadhi S, Advani P, Yang D, Ghosh R, Swaika A, Roy V, et al. Impact of access to NCI- and NCCN-designated cancer centers on outcomes for multiple myeloma patients: a SEER registry analysis. Cancer. 2016;122(4):618–25. doi:10.1002/cncr.29771.CrossRefPubMed Ailawadhi S, Advani P, Yang D, Ghosh R, Swaika A, Roy V, et al. Impact of access to NCI- and NCCN-designated cancer centers on outcomes for multiple myeloma patients: a SEER registry analysis. Cancer. 2016;122(4):618–25. doi:10.​1002/​cncr.​29771.CrossRefPubMed
34.
go back to reference Go RS, Bartley AC, Crowson CS, Shah ND, Habermann EB, Holton SJ, et al. Association between treatment facility volume and mortality of patients with multiple myeloma. J Clin Oncol. 2016;68:3805. Go RS, Bartley AC, Crowson CS, Shah ND, Habermann EB, Holton SJ, et al. Association between treatment facility volume and mortality of patients with multiple myeloma. J Clin Oncol. 2016;68:3805.
36.
go back to reference Durant RW, Wenzel JA, Scarinci IC, Paterniti DA, Fouad MN, Hurd TC, et al. Perspectives on barriers and facilitators to minority recruitment for clinical trials among cancer center leaders, investigators, research staff, and referring clinicians: enhancing minority participation in clinical trials (EMPaCT). Cancer. 2014;120(Suppl 7):1097–105. doi:10.1002/cncr.28574.CrossRefPubMedPubMedCentral Durant RW, Wenzel JA, Scarinci IC, Paterniti DA, Fouad MN, Hurd TC, et al. Perspectives on barriers and facilitators to minority recruitment for clinical trials among cancer center leaders, investigators, research staff, and referring clinicians: enhancing minority participation in clinical trials (EMPaCT). Cancer. 2014;120(Suppl 7):1097–105. doi:10.​1002/​cncr.​28574.CrossRefPubMedPubMedCentral
37.
go back to reference Costa LJ, Hari PN, Kumar SK. Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validity. Leuk Lymphoma. 2016;57(12):2827–32.CrossRefPubMed Costa LJ, Hari PN, Kumar SK. Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validity. Leuk Lymphoma. 2016;57(12):2827–32.CrossRefPubMed
39.
go back to reference Ailawadhi S, Jacobus SJ, Sexton R, Stewart K, Dispenzieri A, Hussein MA, et al. Disease and outcome disparities in multiple myeloma (MM): exploring the role of race/ethnicity and obesity in cooperative group clinical trials. Blood. 2016;128:1192. (Abstract) Ailawadhi S, Jacobus SJ, Sexton R, Stewart K, Dispenzieri A, Hussein MA, et al. Disease and outcome disparities in multiple myeloma (MM): exploring the role of race/ethnicity and obesity in cooperative group clinical trials. Blood. 2016;128:1192. (Abstract)
43.
go back to reference Paulus A, Sharma M, Paulus SM, Menghani R, Rodriguez EM, Frank RD, et al. Genomic variability in multiple myeloma (MM) patients by race: an analysis of the publically available Mmrf Commpass study database. Blood. 2016;128:4432. (Abstract) Paulus A, Sharma M, Paulus SM, Menghani R, Rodriguez EM, Frank RD, et al. Genomic variability in multiple myeloma (MM) patients by race: an analysis of the publically available Mmrf Commpass study database. Blood. 2016;128:4432. (Abstract)
44.
47.
go back to reference Mandelblatt JS, Yabroff KR, Kerner JF. Equitable access to cancer services: a review of barriers to quality care. Cancer. 1999;86(11):2378–90.CrossRefPubMed Mandelblatt JS, Yabroff KR, Kerner JF. Equitable access to cancer services: a review of barriers to quality care. Cancer. 1999;86(11):2378–90.CrossRefPubMed
48.
go back to reference Hashmi S, Mooney C, Phillips GLI, Liesveld JL, Ifthikharuddin JJ. Geographic and racial disparities in multiple myeloma outcomes in the USA. Blood. 2010;116:2557. (Abstract) Hashmi S, Mooney C, Phillips GLI, Liesveld JL, Ifthikharuddin JJ. Geographic and racial disparities in multiple myeloma outcomes in the USA. Blood. 2010;116:2557. (Abstract)
49.
go back to reference Abou-Nassar KE, Kim HT, Blossom J, Ho VT, Soiffer RJ, Cutler CS, et al. The impact of geographic proximity to transplant center on outcomes after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18(5):708–15. doi:10.1016/j.bbmt.2011.08.022.CrossRefPubMed Abou-Nassar KE, Kim HT, Blossom J, Ho VT, Soiffer RJ, Cutler CS, et al. The impact of geographic proximity to transplant center on outcomes after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18(5):708–15. doi:10.​1016/​j.​bbmt.​2011.​08.​022.CrossRefPubMed
50.
go back to reference Abou-Jawde RM, Baz R, Walker E, Choueiri TK, Karam MA, Reed J, et al. The role of race, socioeconomic status, and distance traveled on the outcome of African-American patients with multiple myeloma. Haematologica. 2006;91(10):1410–3.PubMed Abou-Jawde RM, Baz R, Walker E, Choueiri TK, Karam MA, Reed J, et al. The role of race, socioeconomic status, and distance traveled on the outcome of African-American patients with multiple myeloma. Haematologica. 2006;91(10):1410–3.PubMed
52.
go back to reference Aggarwal A, Ginsburg O, Fojo T. Cancer economics, policy and politics: what informs the debate? Perspectives from the EU, Canada and US. J Cancer Policy. 2014;2(1):1–11.CrossRef Aggarwal A, Ginsburg O, Fojo T. Cancer economics, policy and politics: what informs the debate? Perspectives from the EU, Canada and US. J Cancer Policy. 2014;2(1):1–11.CrossRef
Metadata
Title
Equal Treatment and Outcomes for Everyone with Multiple Myeloma: Are We There Yet?
Authors
Sikander Ailawadhi
Kirtipal Bhatia
Sonikpreet Aulakh
Zahara Meghji
Asher Chanan-Khan
Publication date
01-08-2017
Publisher
Springer US
Published in
Current Hematologic Malignancy Reports / Issue 4/2017
Print ISSN: 1558-8211
Electronic ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-017-0393-y

Other articles of this Issue 4/2017

Current Hematologic Malignancy Reports 4/2017 Go to the issue

CART and Immunotherapy (M Ruella, Section Editor)

Targeting Immune System Alterations in Hodgkin Lymphoma

B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (D Persky, Section Editor)

An Update on the Use of Immunotherapy in the Treatment of Lymphoma

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.